All type of patients: 1 trials - Hawk
| durvalumab vs standard treatment | No demonstrated result |
All type of patients: 8 trials - PACIFIC - ARCTIC PD-L1 positive - MYSTIC (combination) - NCT02273375 - CAURAL - NEPTUNE - MYSTIC (monotherapy) - ARCTIC PD-L1 negative
| durvalumab vs placebo | progression or death (progression free survival PFS) by 48% (fully demonstrated) | |
| durvalumab vs Standard of Care | No demonstrated result | |
| durvalumab + osimertinib vs osimertinib | No demonstrated result | |
| durvalumab + tremelimumab vs platinum-based CT | No demonstrated result | |
| durvalumab + tremelimumab vs Standard of Care | No demonstrated result | |
| durvalumab +tremelimumab vs Standard of Care | No demonstrated result |
All type of patients: 2 trials - DANUBE - durvalumab phase 1/2
| durvalumab vs nil | No demonstrated result | |
| durvalumab + tremelimumab vs chemotherapy | No demonstrated result |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
